Patents by Inventor Thomas M. Behr

Thomas M. Behr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha or beta emitters attached to fragments in radioimmunotherapy
    Patent number: 7220399
    Abstract: The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: May 22, 2007
    Assignee: Center For Molecular Medicine and Immunology
    Inventors: David M. Goldenberg, Thomas M. Behr
  • Alpha or beta emitters attached to fragments in radioimmunotherapy
    Publication number: 20040180001
    Abstract: The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
    Type: Application
    Filed: December 1, 2003
    Publication date: September 16, 2004
    Applicant: Center for Molecular Medicine and Immunology
    Inventors: David M. Goldenberg, Thomas M. Behr
  • Alpha or beta emitters attached to fragments in radioimmunotherapy
    Patent number: 6667024
    Abstract: The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: December 23, 2003
    Assignee: Center for Molecular Medicine and Immunology
    Inventors: David M. Goldenberg, Thomas M. Behr
  • Methods for reduced renal uptake of protein conjugates
    Publication number: 20030203836
    Abstract: Kidney uptake of antibody fragment conjugates and protein conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
    Type: Application
    Filed: May 15, 2003
    Publication date: October 30, 2003
    Applicant: Center for Molecular Medicine an Immunology
    Inventors: Thomas M. Behr, David M. Goldenberg
  • METHODS FOR REDUCED RENAL UPTAKE OF PROTEIN CONJUGATES
    Publication number: 20020111300
    Abstract: Kidney uptake of antibody fragment conjugates and protein conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
    Type: Application
    Filed: November 30, 1998
    Publication date: August 15, 2002
    Inventors: THOMAS M. BEHR, DAVID M. GOLDENBERG
  • Methods for reduced renal uptake of antibody fragments
    Patent number: 5843894
    Abstract: Kidney uptake of antibody fragment conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: December 1, 1998
    Assignee: Center for Molecular Medicine and Immunology
    Inventors: Thomas M. Behr, David M. Goldenberg